Who is sponsoring NCT05268341?

NCT05268341 is sponsored by University of Cincinnati.

What drugs are being tested in NCT05268341?

Interventions in NCT05268341: My Sentence Builder.

What condition does NCT05268341 study?

NCT05268341 studies Developmental Language Disorder.

Is NCT05268341 still recruiting?

NCT05268341 is currently recruiting now. Last updated 6 May 2025.

Last reviewed 2025-05-06 · How we verify

NCT05268341

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroimaging Reveals Treatment-related Changes in DLD

Recruiting now NA Last updated 6 May 2025

What this trial tests

NA trial testing My Sentence Builder in Developmental Language Disorder in 184 participants. Currently enrolling.

Timeline

24 May 2022

Primary endpoint
30 June 2027

30 June 2027

Quick facts

Lead sponsor	University of Cincinnati
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	184
Start date	24 May 2022
Primary completion	30 June 2027
Estimated completion	30 June 2027
Sites	6 locations across United States

Drugs / interventions tested

My Sentence Builder

Conditions studied

Developmental Language Disorder — all drugs for Developmental Language Disorder →

Sponsor

University of Cincinnati

Who can join

Adults 48 Months to 71 Months, any sex, with Developmental Language Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Children with developmental language disorders (DLD, aka specific language impairment), a prevalent pediatric disorder, experience hallmark grammar deficits with life-long impacts on educational and occupational outcomes. While effective and early interventions can mitigate the impact of DLD, not enough is known about the neural basis of DLD in young children, yet is needed to inform the design of more individualized interventions. This project uses neuroimaging, along with behavioral methods, with the goal of better understanding the memory-language mechanisms that underlie grammar learning and impairment, while also considering their association to treatment-related changes in preschoolers with DLD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Developmental Language Disorder

Currently open trials in the same condition.

NCT07519629 — Training Caregivers to Teach Vocabulary to Children With Language Impairment · NA · recruiting
NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting
NCT06866223 — Emergent Bilinguals: Child Language Proficiency and Language of Treatment · NA · recruiting
NCT06995014 — Retrieval-based Word Learning in Developmental Language Disorder: Adaptive Retrieval Schedule · NA · recruiting
NCT06340893 — Exercise Training in Children With Communication Impairments · NA · recruiting

Other University of Cincinnati trials

Trials by the same sponsor.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07528638 — Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) · NA · not yet recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07447895 — Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies · NA · not yet recruiting
NCT07231588 — Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05268341 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cincinnati
Last refreshed: 6 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05268341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing